Latest News

Listen: Democratizing CRISPR, drugging the undruggable, and reading pharma’s fine print

Who gets to “play God”? Can old technologies learn new tricks? And what does “drug price” even mean?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Sharon Begley joins us to discuss a fascinating debate in genome editing: The scientific establishment says CRISPR’ing embryos is an ethical nonstarter, but patients with serious inherited diseases see things differently. Then, biotech entrepreneur Michael Gilman dials in to talk about his company’s efforts to craft pills that can do what has thus far proved impossible. Finally, STAT D.C. correspondent Nicholas Florko joins us to break down the murky details of the drug industry’s new transparency initiative.

Read the rest…

Source link

Related posts

BMA hero scoops NHS award


New screening strategy identifies novel inhibitors that may help develop cure for Parkinson's


Discovery may provide clues for treatment of autism and schizophrenia


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy